Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,228 stopped studies mapped to Malignant Digestive System Neoplasm and descendants · 91% state a reason
Over the 2,228 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02116322 | Endoscopic Ultrasound (EUS) Guided Fine Needle Aspiration (FNA) EUS-FNA of Solid… | N/A | terminated | Apr 16, 2014 | Johns Hopkins University | The study stopped as the used needle was difficult to maneuver in the corkscrew method being… | Other (stated, no rule matched) |
| NCT01847599 | Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib(ProMETheX) | N/A | terminated | May 7, 2013 | Centre Jean Perrin | interim analysis : discontinuation for efficacy of the intervention | Efficacy / futility |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | Phase 2 | withdrawn | Apr 9, 2014 | Academic and Community Cancer Research United | not stated | Not stated |
| NCT00002664 | Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With… | Phase 2 | withdrawn | May 24, 2004 | James Ahlgren | No recruitment | Enrollment / accrual |
| NCT01309126 | Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or…(PRIMUS) | Phase 3 | terminated | Mar 4, 2011 | HiberCell, Inc. | Due to enrollment challenges resulting from changing treatment patterns in the use of cetuximab,… | Enrollment / accrual |
| NCT00085410 | Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic… | Phase 2 | terminated | Jun 11, 2004 | National Cancer Institute (NCI) | The trial was discontinued early due to no confirmed partial responses. | Other (stated, no rule matched) |
| NCT01095523 | Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS… | Phase 2 | withdrawn | Mar 30, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of… | Phase 1 / Phase 2 | withdrawn | Aug 6, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01386502 | CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors | Phase 1 | withdrawn | Jul 1, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01936961 | Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid…(I-CREST) | N/A | withdrawn | Sep 6, 2013 | Western Regional Medical Center | No patients enrolled | Enrollment / accrual |
| NCT00039078 | Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer… | Phase 2 | withdrawn | Jan 27, 2003 | Allan Tsung | Record created in error - not a research study | Other (stated, no rule matched) |
| NCT01774851 | A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of… | Phase 2 | terminated | Jan 24, 2013 | Merrimack Pharmaceuticals | DSMB recommendation due to lack of efficacy. There were no safety signals. | Safety / toxicity |
| NCT00408772 | Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency… | Phase 2 | withdrawn | Dec 7, 2006 | University of California, Davis | Lack of accrual | Enrollment / accrual |
| NCT01515046 | Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer(PACMAN-II) | Phase 2 | terminated | Jan 23, 2012 | Joseph J. Cullen | Standard of care changed to FOLFIRINOX; poor accrual. | Enrollment / accrual |
| NCT00787787 | Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic… | Phase 2 | terminated | Nov 10, 2008 | University of Washington | not stated | Not stated |
| NCT02856568 | Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With… | Phase 1 | withdrawn | Aug 5, 2016 | Mayo Clinic | Site dropped study | Other (stated, no rule matched) |
| NCT01303159 | Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile… | N/A | terminated | Feb 24, 2011 | Weill Medical College of Cornell University | EndoHPB probe is FDA approved and considered standard of care | Other (stated, no rule matched) |
| NCT00841035 | 7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in… | Phase 2 | terminated | Feb 11, 2009 | University of Alabama at Birmingham | Sponsor stopped due to slow enrollment | Enrollment / accrual |
| NCT01940237 | A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients… | N/A | terminated | Sep 12, 2013 | New York State Psychiatric Institute | Low recruitment | Enrollment / accrual |
| NCT02243007 | Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients… | Phase 2 | terminated | Sep 17, 2014 | Massachusetts General Hospital | Slow Accrual | Enrollment / accrual |
| NCT01355302 | E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine… | Phase 1 / Phase 2 | terminated | May 18, 2011 | Eisai Inc. | Sites not recruiting | Enrollment / accrual |
| NCT02202759 | A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction | Phase 2 | terminated | Jul 29, 2014 | Millennium Pharmaceuticals, Inc. | Business Decision, No Safety or Efficacy Concerns | Safety / toxicity |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | Phase 2 | terminated | Jul 29, 2014 | Millennium Pharmaceuticals, Inc. | Business Decision, No Safety or Efficacy Concerns | Safety / toxicity |
| NCT02417753 | AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites | Phase 2 | terminated | Apr 16, 2015 | National Cancer Institute (NCI) | Study was closed because we could not find these types of patients. | Other (stated, no rule matched) |
| NCT01641939 | A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal… | Phase 2 / Phase 3 | terminated | Jul 17, 2012 | Hoffmann-La Roche | not stated | Not stated |
| NCT00449163 | Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal… | Phase 2 | terminated | Mar 19, 2007 | University of Miami | Study terminated by University of Miami Institutional Review Board | Other (stated, no rule matched) |
| NCT00948688 | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | Phase 1 / Phase 2 | terminated | Jul 29, 2009 | Massachusetts General Hospital | Funding was withdrawn after only 10 participants were enrolled | Enrollment / accrual |
| NCT01005875 | Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma(RAD 0901) | N/A | terminated | Nov 2, 2009 | University of Alabama at Birmingham | Sponsor(Bayer)did not wish to continue with study due to slow accrual. Therefore, there is… | Enrollment / accrual |
| NCT00524316 | Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be… | Phase 2 | terminated | Sep 3, 2007 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT01326065 | Implementation of Laparoscopy-assisted Surgery for Colon Cancer | — | terminated | Mar 30, 2011 | Helse Stavanger HF | Study had to be terminated due to lack of funding | Funding |
| NCT01646554 | Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With…(BOS3) | Phase 2 / Phase 3 | withdrawn | Jul 20, 2012 | European Organisation for Research and Treatment of Cancer - EORTC | not stated | Not stated |
| NCT01942083 | A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to… | Phase 1 | terminated | Sep 13, 2013 | Korea Otsuka Pharmaceutical Co., Ltd. | Company decision | Sponsor / business decision |
| NCT02856867 | Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric…(MEGAN) | Phase 2 | withdrawn | Aug 5, 2016 | European Organisation for Research and Treatment of Cancer - EORTC | not stated | Not stated |
| NCT00604266 | Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar…(PET/MRCP) | — | withdrawn | Jan 30, 2008 | University of Toronto | not stated | Not stated |
| NCT01379521 | Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC(TRACER) | Phase 2 | terminated | Jun 23, 2011 | Novartis Pharmaceuticals | The study was terminated due to low enrollment. This resulted in the study being underpowered and… | Enrollment / accrual |
| NCT02207959 | Gastric In Vivo Study | Phase 1 | terminated | Aug 4, 2014 | Susana Gonzalez | PI left institution | Investigator |
| NCT02227914 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced… | Phase 1 / Phase 2 | withdrawn | Aug 28, 2014 | Amgen | Study stopped due to administrative reasons | Other (stated, no rule matched) |
| NCT02277093 | Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer | Phase 2 | terminated | Oct 28, 2014 | Washington University School of Medicine | FDA issued a clinical hold as pacritinib had increased side effects | Other (stated, no rule matched) |
| NCT00455091 | A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma | — | terminated | Apr 3, 2007 | National Health Research Institutes, Taiwan | No cases enrollment | Enrollment / accrual |
| NCT01814345 | Her 2 Testing in Indian Patients With Gastric Cancer | — | terminated | Mar 19, 2013 | Tata Memorial Hospital | not stated | Not stated |
| NCT02060669 | Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer | Phase 3 | terminated | Feb 12, 2014 | Samsung Medical Center | others | Other (stated, no rule matched) |
| NCT01171482 | Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular… | Phase 2 | terminated | Jul 28, 2010 | Seoul National University Hospital | There were problems with national reimbursement policies. | Other (stated, no rule matched) |
| NCT02997956 | Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing… | Phase 1 / Phase 2 | withdrawn | Dec 20, 2016 | University of Michigan Rogel Cancer Center | funding issues | Funding |
| NCT01543607 | Endoscopic Therapy of Malignant Bile Duct Strictures | N/A | terminated | Mar 5, 2012 | Massachusetts General Hospital | Lack of enrollment | Enrollment / accrual |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be… | Phase 1 | withdrawn | Oct 5, 2015 | National Cancer Institute (NCI) | Other- Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT01849588 | HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) | Phase 4 | terminated | May 8, 2013 | Massachusetts General Hospital | Slow Accrual | Enrollment / accrual |
| NCT02819869 | The Combination Effect of Statin Plus Metformin on Relapse-free | Phase 2 | terminated | Jun 30, 2016 | Taipei Medical University WanFang Hospital | insufficient for the fund | Funding |
| NCT03117855 | Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct… | Phase 1 | withdrawn | Apr 18, 2017 | City of Hope Medical Center | Company no longer interested in supporting this trial | Sponsor / business decision |
| NCT02413853 | Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients…(PRIMIER) | Phase 2 | withdrawn | Apr 10, 2015 | University of Southern California | Study drug supply issues | Drug supply |
| NCT03026803 | A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer | Phase 2 | terminated | Jan 20, 2017 | City of Hope Medical Center | Due to Sorafenib became first line treatment for HCC, the designed treatment became less… | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Jul 24, 2017source: clinicaltrials